Journal
ACS CHEMICAL NEUROSCIENCE
Volume 10, Issue 11, Pages 4633-4642Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.9b00469
Keywords
Alzheimer's disease; A beta 40; fibrils; inhibitors; peptide; gold nanoclusters
Funding
- Natural Science Foundation of China [21575102]
- Tianjin Scientific Program [18ZYPTJC00020]
- Open Funds of the State Key Laboratory of Electroanalytical Chemistry [SKLEAC201911]
Ask authors/readers for more resources
The abnormal aggregation of amyloid beta (A beta or A beta) from monomeric proteins into amyloid fibrils is an important pathological contact to Alzheimer's disease (AD). Amyloid beta 40 (A beta 40 ), the pivotal biomarker of AD, aggregates to form amyloid plaques. For this reason, inhibition of amyloid fibrillation had become a crucial prevention and therapeutic strategy. Usually, LVFFA is the central hydrophobic fragment of A beta and can inhibit the aggregation of A beta 40. In this work, in order to improve the inhibitory ability of LVFFA, hexapeptide CLVFFA were conjugated at the surface of Au clusters (AuNCs) to manufacture a nanosized inhibitor, AuNCs-CLVFFA. Thioflavin T fluorescence and transmission electron microscope results showed that AuNCs-CLVFFA inhibited A beta 40 fibrillogenesis, fibrils' prolongation, and mature fibrils' disaggregation. Furthermore, AuNCs as the backbone of the inhibitor showed extraordinary inhibition ability for A beta 40 aggregation at a low AuNCs-CLVFFA concentration. Free hexapeptide CLVFFA, at the same concentration, showed almost no inhibition. Additionally, the inhibitor could maintain the optical properties of nanoclusters, and the cell viability demonstrated that the inhibitor had good biocompatibility and may potentially be applied into AD therapy or treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available